Anti-hyperlipidemic agents, also called lipid-lowering drugs, any drug that lowers the levels of lipids and lipoproteins (lipoprotein complexes) in the blood.
This report contains market size and forecasts of Anti-hyperlipidemic Agents in global, including the following market information:
Global Anti-hyperlipidemic Agents Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Anti-hyperlipidemic Agents Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Anti-hyperlipidemic Agents companies in 2021 (%)
The global Anti-hyperlipidemic Agents market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Statins Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anti-hyperlipidemic Agents include Merck, Biocon, Concord Biotech, Aurobindo Pharma, Teva Pharmaceutical Industries, Mylan, Novartis, Sun Pharmaceutical Industries and Abbott, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-hyperlipidemic Agents manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-hyperlipidemic Agents Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-hyperlipidemic Agents Market Segment Percentages, by Type, 2021 (%)
Statins
Fibrates
Niacin
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Global Anti-hyperlipidemic Agents Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-hyperlipidemic Agents Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-hyperlipidemic Agents Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-hyperlipidemic Agents Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-hyperlipidemic Agents revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Anti-hyperlipidemic Agents revenues share in global market, 2021 (%)
Key companies Anti-hyperlipidemic Agents sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Anti-hyperlipidemic Agents sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Biocon
Concord Biotech
Aurobindo Pharma
Teva Pharmaceutical Industries
Mylan
Novartis
Sun Pharmaceutical Industries
Abbott
Lonza
Jubilant Life Sciences
Vertellus
Brother Enterprises
Esperion Therapeutics
FORMAC Pharmaceuticals
Waterstone Pharmaceuticals
Hanmi Fine Chemical
Dr. Reddy’s Laboratories
Rochem International
Tecoland
Glenmark Pharmaceuticals
Neuland Laboratories
Lupin
Saptagir Laboratories
Lusochimica
Jiangsu Hansyn Pharmaceutical
Changzhou Pharmaceutical Factory
WUHAN ZY PHARMACEUTICAL CO LTD
Fuan Pharmaceutical
Vanetta